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Abstract
Health economic evaluations are commonly conducted through a cost-utility analysis, where
health benefits are measured using utility scores. A common utility measure is the European
Quality of Life (EQ-5D). Osteoarthritis (OA) research studies commonly use disease-specific
quality of life tools such as the Western Ontario and McMaster’s Universities Osteoarthritis
Index (WOMAC) to derive utility scores, but the validity of this method is unknown. This
research aims to determine the agreement between utility scores derived from WOMAC and the
EQ-5D surveys among patients who have undergone Total Joint Replacement (TJR). To estimate
the agreement, we calculated an intraclass correlation coefficient (ICC) and its 95% confidence
interval (CI) and produced Bland Altman plots. Our results indicate good agreement between the
two scores, as seen with the ICC value of 0.85, 95% CI (0.82 - 0.87).

Keywords: Total joint replacement; cost-utility analysis; mapping; EQ-5D-5L; WOMAC;
Osteoarthritis
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Summary for Lay audience
Osteoarthritis is a common chronic condition that affects the function of the joints. With a
prevalence rate of 14.2% and projections indicating that the number of Canadians diagnosed with
OA is set to increase, the economic burden posed by OA is also set to increase. Canadians rely on
the publicly funded healthcare system to meet their healthcare needs. One of the significant issues
with publicly funded healthcare programs is that the needs of the public outweigh the available
healthcare resources. Therefore, decision-makers need to identify which healthcare needs will
provide the greatest benefit to the largest possible majority of the public; since each decision comes
with a cost and benefit. One of the methods often employed within healthcare to identify the costs
and benefits associated with each of these decisions is the use of health economic evaluations.
With an increasingly aging population and the projected number of patients with OA, the resources
required to treat these individuals will increase. As a result, more economic evaluations are being
conducted within osteoarthritis research. An essential metric within these evaluations are utility
scores. A utility score is a numerical value representing a patient’s preference for each health state,
with a value of 1 representing perfect health and 0 representing the worst imaginable health state
from the patient’s perspective. These values can be derived either directly using utility instruments
or by converting disease-specific quality of life surveys into utility scores. However, the validity
of converting disease-specific scores into utility scores following total joint replacement is
unknown.
Therefore, this thesis aims to compare the utility scores between the European Quality of Life (EQ5D-5L) and the Western Ontario and McMasters Osteoarthritis Index (WOMAC) among patients
who have undergone total joint replacement surgery of the hip and or knee joints.

iii

iv

Co-Authorship Statement
The study was conceptualized and designed by my supervisor Dr. Jacquelyn Marsh, with support
from my advisory committee members Dr. Edward Vasarhelyi and Dr. Lyndsay Somerville. I was
responsible for writing and running analysis on R. Dr. Marsh and Dr. Somerville revised the
manuscript assisted in interpreting the results and provided valuable feedback for the final thesis
submission.

iv

v

Acknowledgement
I would also like to thank my family for supporting me throughout the Masters program.
I want to thank my supervisor Dr. Jacquelyn Marsh for supporting me throughout the thesis writing
process and helping me navigate through the Masters’ program over the last 2 years and for
providing me with the opportunity to learn at Western.
I would also like to acknowledge and thank Dr. Lyndsay Somerville, for providing us with
feedback on our thesis and for her help in obtaining the data for this thesis.
I would like to acknowledge the immense help provided by Dr. Jacquelyn Marsh, Dr. Lyndsay
Somerville, Dr. Edward Vasarheyli for supporting me as my committee members.
Finally I would like to thank all my course instructors for all their support.

v

vi

Table of Contents
Abstract ............................................................................................................................... ii
Summary for lay audience ................................................................................................. iii
Co-Authorship Statement................................................................................................... iv
Acknowledgments............................................................................................................... v
List of Tables ..................................................................................................................... ix
List of Figures ..................................................................................................................... x
List of Appendices ............................................................................................................. xi
List of Abbreviations ........................................................................................................ xii
CHAPTER 1…………………………………………………………………………….....1
1.1 Introduction .............................................................................................................. 1
1.2 Literature Review ..................................................................................................... 2
1.2.1 Osteoarthritis: detection and treatments ........................................................ 2
1.2.1.1 Diagnosis ....................................................................................... 3
1.2.1.2 Types of non-operative treatments ................................................ 3
1.2. 2. OA – Hip and knee...................................................................................... 4
1.2.2.1 Total Joint Replacement (TJR) ..................................................... 4
1.3 Economic Burnden ................................................................................................... 5
1.3.1 Economic Evaluation ...................................................................... 6
1.4 Utility scores ............................................................................................................ 7
1.5 Patient Reported Outcome Measures (PROM)s ...................................................... 7
1.5.1 Disease Specific Measures .............................................................. 8
1.5.2 Western Ontario and McMasters’ Osteoarthritis Index (WOMAC)9
1.5.3 Generic surveys ............................................................................. 10
1.6 Preference Based Measurements (PBM) ............................................................... 10
vi

vii

1.6.1 EuroQol (EQ-5D-5L) .................................................................. 12
1.7 Orthopedic studies and cost-utility studies ............................................................ 13
1.8 Mapping Algorithms .............................................................................................. 15
1.9 Purpose ................................................................................................................... 17
CHAPTER 2 ..................................................................................................................... 18
2 METHODS ................................................................................................................. 18
2.1 Study design ......................................................................................................... 18
2.2 Eligibility Criteria ................................................................................................ 18
2.2.1 Sample Size ................................................................................... 18
2.2.2 Data collection .............................................................................. 19
2.3 Outcome measures ................................................................................................. 20
2.4 Mapping algorithm ................................................................................................. 20
2.5 Plan of analysis ...................................................................................................... 21
2.5.1 Agreement .................................................................................... 21
2.5.2 Validity.......................................................................................... 22
2.5.3 Mean difference in utility scores ................................................... 22
2.5.4 Bland Altman Plot ......................................................................... 22
2.6 Outliers ................................................................................................................... 23
CHAPTER 3 ..................................................................................................................... 24
3.0 Results ...................................................................................................................... 24
3.1 Mapping Algorithms .............................................................................................. 25
3.2 Agreements ............................................................................................................ 26
3.2.1 Agreement between utility values ................................................. 26
3.3 Validity................................................................................................................... 27
3.3.1 Normality plots of data................................................................... 28
vii

viii

3.3.2 Linear regression analysis. ..................................................... 31
3.4 Mean difference in utility scores ............................................................................ 32
3.5 Bland Altman Plots ................................................................................................ 33
3.6 Outliers ................................................................................................................... 36
CHAPTER 4 ..................................................................................................................... 39
4.0 Discussion ................................................................................................................ 39
4.1 Strenghts and limitations.......................................................................................... 42
CHAPTER 5 ..................................................................................................................... 43
5.0 Conclusion .................................................................................................................. 43
5.1 Future directions..................................................................................................... 43
References ......................................................................................................................... 44
Appendices ........................................................................................................................ 51
Curriculum Vitae .............................................................................................................. 61

viii

ix

List of Tables
Table 3.1 Demographics Table ......................................................................................... 24
Table 3.2 Summary table for predicted and observed utility scores ................................. 25
Table 3.3 Intraclass Correlation (ICC) for subgroups ...................................................... 27
Table 3.4 Linear regression............................................................................................... 31
Table 3.5Mean Differences and Confidence intervals ...................................................... 33

ix

x

List of Figures
Figure.3.1 Normality plots for the linear model .............................................................. 28
Figure.3.2 Histogram for observed values ........................................................................ 30
Figure.3.3 A histogram for predicted values .................................................................... 31
Figure.3.4 Linear regression for predicted and obseved utility scores ............................. 32

Figure.3.5 Bland Altman plot comparing the two methods for the entire sample ............ 33

Figure.3.6 Bland Altman plot for subgroup 1…………………...………………………..34
Figure.3.7 Bland Altman Plot for subgroup 2................................................................... 35

Figure.3.8 Bland Altman Plot for subgroup 3................................................................... 35

Figure.3.9 Bland Altman Plot for subgroups 4 ................................................................. 36

Figure.3.10 Boxplots for predicted utility values from the WOMAC survey and the observed
utility values from the EQ-5D-5L ................................................................................ 37
Figure.3.11 Bland Altman plot with the outliers removed ............................................... 38
Figure.3.12 Bland Altman plot for outliers that were common for both surveys ............. 38

x

xi

List of Appendices

Appendix A : Ethics Approval ................................................................................................ 51

Appendix B : EQ-5D-5L survey sample ................................................................................. 53

Appendix C: Womac survey sample....................................................................................... 55

Appendix D: Outliers tables for both the predicted utility scores from the WOMAC survey and
the observed utility score from the EQ-5D-5L survey............................................................ 58

xi

xii

List of Abbreviations
BMI

Body Mass Index

CI

Confidence Interval

CUA

Cost Utility Analysis

EQ-5D-5L

EuroQol- 5D-5L

GLM

General Linear Model

OA

Osteoarthritis

PBM

Preference Based Measure

PROM

Patient report outcome measure

QALYs

Quality adjusted life years

SD

Standard deviation

SEM

Standard Error of Measurement

SG

Standard Gambit

TTO

Time Trade Off

THR

Total Hip Replacement

TJR

Total Joint Replacement

TKR

Total Knee Replacement

WOMAC

Western Ontario and McMaster Universities Osteoarthritis Index

xii

1

Chapter 1
1.1Introduction
Osteoarthritis (OA) is a disease that affects the entire joint, involving the cartilage, joint lining,
ligaments, and bone. It is characterized by breakdown of the cartilage, bony changes of the
joints, deterioration of tendons and ligaments, and inflammation of the synovium or joint lining.
(Kraus, et al., 2015;OARSI, 2016). Birthwhistle and colleagues (2015) has estimated the
prevalence of OA in Canada stands at 14.2%, with women being more effected by the disease
than men (15.6% vs 12.4%). As of 2010, OA-related care accounts for 2.9 billion dollars, and
projections indicate that the number of individuals diagnosed with OA is set to increase in the
coming years (Sharif et al., 2015; Stats Canada, 2019). With a rapidly aging population,
combined with increased constraints on healthcare budgets, there is a clear need for the optimal
allocation of these scarce healthcare dollars. An effective way to assess the value of health care
programs is through health economic evaluations. Utility measures provide information
regarding an individual’s preference for health states and can be obtained through two methods.
The first is to elicit preferences for health states directly through choice-based exercises such as
the Time Trade-Off (TTO) and Standard Gamble (SG) techniques; however, these are timeconsuming and burdensome for the patient and require specialized training for administration.
Therefore, a common approach is using existing health-related quality of life questionnaires.
Prescaled indexes are self-reported questionnaires that provide a utility value for each possible
health state. Another method that is increasingly being used is to convert scores from HRQOL
instruments into utility scores using algorithms; however, the validity of this method has mixed
results and agreement between utility scores from a preference-based utility measure and a
converted disease-specific measure among patients following total joint replacement is unknown.
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Therefore, the primary objective of this thesis was to assess the agreement between the EQ-5D
utility scores and utility scores generated by converting WOMAC scores among patients who
have undergone hip and knee replacement.

1.2 Literature review
1.2.1 Osteoarthritis: detection and treatments
Osteoarthritis (OA) is a disorder of the whole joint that is the result of stress and changes to
weight bearing joints of the body resulting from the breakdown of cartilage within the joints,
inflammation, bone remodelling and loss of function for the joint (OARSI, 2016). It is a form of
arthritis that commonly affects more women than men (Hawker, 2019). OA results in increased
pain and reduced function of the joints, with the hips, knee, and spine being most affected due to
the wear and tear of the cartilage (Xie et al., 2010). Cartilage refers to a soft and flexible
connective tissue that sits between bones and helps mitigate friction between the bones in a joint.
However, through the continuous use of joints throughout life, cartilages become thinner,
resulting in greater friction between the joints, contributing to greater pain and a decrease in
function of the joint.
Factors that contribute to the increased prevalence of OA within the Canadian population include
age; sex; obesity; genetic predisposition; socio-economic status; high blood pressure; high bone
mineral density; physically demanding jobs; injuries to the joint; weakness in muscles
surrounding the joint; deformities in the joints; malalignment of the joints and participation in
high – performance sports (Allen et al., 2022).
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In Canada, 26.8% of adults (18 and over) are obese, and with a rapidly aging population that is
projected to account for 23% of the population by 2030, the prevalence of OA is expected to
increase. Furthermore, as more adults get diagnosed with OA and as non-operative forms of
treatments lose their efficacy in reducing pain and maintaining function for the joints, the
demand for total joint replacement surgeries (hip and knee) will increase.

1.2.1.1 Diagnosis
Globally, OA affects 240 million people over the age of 60 (Allen, et al., 2022). Typically, they
present with symptoms such as joint pain, limited functions related to the joints and familial
history. Physicians can use medical imaging technologies like X-ray machines to diagnose the
magnitude of osteoarthritis's effect on the joints. A common radiographic grading technique used
to classify patients with OA based on severity was first introduced by Kellgren and Lawrence in
1957, the KL classification for Osteoarthritis (Kellgren & Lawrence, 1957). The KL
classification system is divided into grades 0 – 4 ( 0-None, 1 – doubtful, 2- minimal, 3 –
Moderate and 4 – Severe). With each increasing grade, the space between the joints on the x-rays
becomes narrower until there is no space between the joints (Grade 4 – severe Osteoarthritis).
The visualized space on the x-rays represents the presence of cartilage and the lack of
osteophytes.

1.2.1.2 Types of non-operative treatments
Treatments for OA vary depending on the level of severity of the disease. Common forms of
treatment for those diagnosed with grade 2 or minimal OA on the KL scale include physical
therapy, exercise regimens, injections, and pharmacological interventions such as non-Steroidal
Anti-Inflammatory Drugs (NSAIDs). Meta-analyses have shown small to moderate effect sizes
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in improving pain management for patients with OA where physical therapy and NSAIDs are
used in conjunction (Yu & Hunter,2015).
Clinical practice guidelines for non-operative management of OA suggest that exercises aimed at
maintaining the functionality of the joints, educational programs for self-management of OA and
programs aimed at changing dietary behaviour to reduce obesity are shown to be highly
effective. Additionally, pharmaceutical options such as NSAIDs, topical treatments, and opioids
have also shown to be effective means for non-operative management of OA (AAOS, 2021;
OARSI, 2019). Similar evidence has been presented by Kolanski and colleagues (2020), where
the strongest recommendation for non-operative management of OA were exercises such as
walking, neuro-muscular training and aquatic exercises; weight loss; Tai Chi; Yoga; the use of
canes; Tibo-femoral knee braces; and Patellofemoral knee braces (Kolasinski et al., 2020).

1.2.2 Hip and Knee OA
Globally as of 2022, 240 million patients have been diagnosed with symptomatic OA. Multiple
cohort studies have indicated that the prevalence and incidence rates for knee OA remain the
highest, followed by hip and hand OA. The prevalence rates have been estimated as high as 14%
in the US for hip OA and 7% for knee OA (Allen et al., 2022). Additionally, according to the
Canadian Joint Replacement Registry (CJRR), OA accounts for 72.5% and 99.4% of primary hip
and knee replacements across Canada. (CIHI, 2020).

1.2.2.1 Total joint replacement (TJR)
Total joint replacement is recommended for individuals with severe OA (grade 4 on the KL
scale) or once non-operative interventions have been exhausted. TJR is a surgical procedure that
replaces the joints within the body with metal or plastic components. The prosthetic joints aim to
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reduce pain, improve function, and restore mobility for patients to provide a greater quality of
life. In Canada, a total of 63,496 hip replacements and 75,073 knee replacements were performed
between 2019-2020, with women accounting for 58% of all surgeries (Canadian Institute for
Health Information. Hip and Knee Replacements in Canada: CJRR Annual Statistics Summary,
2018–2019. Ottawa, ON: CIHI; 2020.).

1.3 Economic Burden
In 2010 OA-related care accounted for $2.9 billion in Canada and is expected to increase to $ 7.9
billion by 2031; (Sharif et al., 2015). The projected costs for hospitalizations are $2.9 billion; $
1.2 billion for outpatient services; $1.2 billion for alternative treatments and out-of-pocket costs;
$ 1 billion for drugs; $ 0.7 billion for rehabilitation; and $0.6 billion for treating side effects
caused by drugs (Sharif et al., 2015). Additionally, the inpatient cost of performing TKR and
THR in Canada as of 2020 was $ 10,500 (Canadian Institute for Health Information. Hip and
Knee Replacements in Canada: CJRR Annual Statistics Summary, 2018–2019. Ottawa, ON:
CIHI; 2020.). The CJRR 2019-2020 report stated that $1.4 billion was spent on these surgeries.
Similarly, between 2015 to 2020, the national average for the percentage of change was 19.3%,
indicating the rapid increase in the number of these surgeries being performed within that
timeframe.
The economic burden posed by the increased prevalence of OA was examined by Tarride and
colleagues (2012) for the province of Ontario by evaluating the results of Ontarians who
completed the Canadian Community Health Survey (CCHS). Their study indicated that patients
diagnosed with OA had higher hospitalization costs than those without; $2233 vs $1033,
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respectively (Tarride et al., 2012). The average cost for primary knee replacements in Canada
was $9,083 and $9,591 for primary hip replacements for OA; these figures include physician
costs (CIHI, 2021). It should be noted that their estimates are only for those diagnosed with OA
and do not account for primary replacement of the hip due to hip fractures or any revision
surgeries after TJR.
In a systematic review of the economic burden of OA, the direct costs ranged from $ 1442 to $
21,335 annually in the United States (Xie et al., 2016). Xie and colleagues also noted that the
increased burden of cost varied depending on the level of access individuals had to healthcare,
but the costs remained high. In contrast, the quality of life for patients remained low (Xie et al.,
2016). Similarly, the estimated productivity costs from work loss associated with patients
diagnosed with OA in Canada between 2010 to 2031 are $ 12 billion to $ 17.5 billion (Sharif et
al., 2017). These estimates provide a clear view of the economic and social burden that OA is
expected to bring about with its increasing prevalence and highlights the need for economic
evaluations to identify the best strategies to help address the issue.

1.3.1 Economic Evaluation
Health economic evaluations are a research methodology aimed at estimating the additional costs
of treatment relative to the benefits achieved compared to the standard of practice. Health
economic evaluations allow decision-makers to understand how worthwhile a new treatment
might be for patients. With the increasing scarcity of healthcare dollars, the need for more costeffective options has become more pronounced within the Canadian healthcare system. Multiple
forms of health economic evaluations exist depending on the outcome of interest measured. The
two main types of economic evaluation in healthcare are cost-effectiveness analysis (CEA) and
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cost-utility analysis (CUA). CEA is a type of economic evaluation where the measurement of
cost is in healthcare dollars while the measurement of effect is in natural units such as the
number of life years gained, falls prevented, adverse events, quality of life, weight loss, or any
outcome of interest, depending on the clinical area. With CUA, on the other hand, the
measurement of cost is in healthcare dollars, while the measurement of effect is in qualityadjusted life years (QALYs) (Drummond et al.,2015). CUA uses utility scores, a preferencebased quality of life measure, to calculate quality-adjusted life years.

1.4 Utility Scores
Utility refers to the patient’s preference for each health state. Utility scores range between 0 and
1; 0 represents a health state equivalent to death for a patient, while 1 represents a perfect health
state and utility values below 0 or negative utility values represent health states that are
considered worse than death by patients.
Utility scores are an integral part of CUA for health economic studies as they are used to
calculate quality-adjusted life years (QALY)s. QALYs are a summary value that accounts for
both the quality and quantity of life that patients spend in a particular health state. CUA reports
the additional cost per QALY gained when comparing a new treatment to the current standard of
care. QALYs are a useful outcome within health economic evaluations as they allow for the
comparison of the cost-effectiveness of various treatments across studies and clinical areas
(Whitehead and Ali, 2019).

1.5 Patient-reported Outcome Measures
Patient-reported outcomes measures (PROMS) represent measurements obtained from patients
about specific outcomes of interest through self-administered surveys. These measures provide a
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quick overview of a patient's health from their perspective and can be used to track the progress
of the disease by administering the survey multiple times to determine the relative change in the
severity of the disease over time or to evaluate the effectiveness of an intervention, such as
through pre and post-treatment surveys. PROMs can be divided into; disease-specific, which
relate to a specific health condition or region-specific, which assess specific areas of the body;
and generic PROMs, which evaluate the overall quality of life.

1.5.1 Disease-Specific Measures
Disease-specific outcome measures are questionnaires that relate to a particular disease or health
condition and evaluate the patient's health status in domains specific to the condition of interest.
Disease-specific measures provide researchers and clinicians with the ability to understand how
far a disease has progressed from a patient’s perspective through domains that are geared
towards assessing certain aspects of the patient’s physical health that have been known to be
most affected by a disease. While these domains and their descriptions provide a glimpse of how
the disease has affected a patient’s daily activity of living, it does not, however, provide reliable
information on the overall wellbeing of the individual, nor can the findings from such surveys be
applied to a border disease population or a general population. In addition, disease-specific
measures are highly sensitive and specific compared to generic measures since they were made
to detect those changes that could only be found within a specific patient population. Within the
field of hip and knee OA, one of the more established surveys commonly used in clinical
research is the Western Ontario and McMaster's Osteoarthritis Index (WOMAC).
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1.5.2 WOMAC
The WOMAC was first developed in the 1980s and has become a staple to measure status after
osteoarthritis treatment relating to the hip and knee. The questionnaire includes three domains:
pain, stiffness, and physical functioning. The three domains with 24 questions are primarily used
to assess the impact of OA on a patient's daily life activities (ADL), functionality, gait, overall
health, and QOL. Each question is rated on a scale between 0 and 4 (0 – none, 1 - slight, 2 –
moderate, 3 – severe, and 4 – extreme), resulting in scores for each domain which are then added
together to compute a final total WOMAC score.
A systematic review by McConnel and colleagues (2001) looked at studies that utilized the
WOMAC within a population diagnosed with OA of the hip or knee and indicated that WOMAC
had good reliability, as the survey displayed high internal consistency with Cronbach Alpha
values being above 0.7 across multiple studies. Their review also provided evidence that the
survey had good construct and known groups validity. Additionally, their review indicated that
the survey was responsive, but the physical domain had the largest effect size, while the pain and
stiffness subscales had significantly smaller effect sizes; indicating that the physical sub-scale
could easily detect change that was clinically significant within a smaller sample population as
opposed to the other subscales (McConnel et al., 2001). Similarly, the physical function subscale
has been shown to have very good reliability, good validity, good sensitivity to change and good
responsiveness when compared to similar surveys such as the Knee Injury and Osteoarthritis
Outcome Score (KOOS) that specifically assess the physical functioning of the hip or knee for
OA patients (White & Master, 2016).
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Similarly, a systematic review by Lundgren-Nilsson and colleagues (2018) summarized the
psychometric properties of PROMs used in OA by assessing their validity, reliability, and
feasibility based on the outcome measures in the Rheumatology (OMERACT) filter. Their
summary pointed out that the WOMAC had strong validity and reliability with moderate levels
of feasibility or ease of use for patients (Lundgren-Nilsson et al., 2018).

1.5.3 Generic surveys
Generic measures are a type of PROM that ask participants to rate their health status or quality of
life without references to specific diseases and provide users with a holistic view of health.
Unlike disease-specific measures, generic surveys are designed to assess the overall wellbeing of
individuals and seek to identify areas of health that are commonly affected in patients regardless
of the disease. This means that the results of these surveys are highly generalizable to a broader
patient population compared to disease-specific surveys. The survey's ability to be used across
multiple disease populations makes these surveys ideal for health economic evaluations that seek
to evaluate the costs and benefits of different treatments across various populations.

1.6 Preference-based Measures
Preferences can be measured using two methods; direct elicitation from participants or through
the use of pre-scored health status indexes. Direct elicitation typically refers to methods where
patients are provided alternative options and are asked to decide on which option they prefer.
Direct elicitation methods include visual analog scale (VAS), standard gamble (SG), and time
trade-off (TTO) methods. The VAS is a method where patients are asked to rate their health on a
scale varying from 0 to 100, 0 to 10 or by simply placing a line on a horizontal line where one
end represents the worse possible health and the other end represents the best possible health
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state. In the case of rating health through numerical values, the higher values indicate better
health and lower values indicate low levels of health (Drummond et al., 2015). The SG is another
method of direct elicitation where participants are provided two options. Alternative one is
taking a treatment with the possibility of going back to complete health and living for a specified
number of years or dying immediately. While alternative two results in the patient remaining in
the current health state for a specified number of years. The point where the patient preference
for alternatives 1 and 2 becomes the same represents the utility value for that health state.
Finally, the TTO is another elicitation method where patients are provided two alternatives, like
with the SG, however, the amount of time in a health state of perfect health (1) vs at a lower
level of health (i) is varied; as the name implies, this method seeks to identify the amount of time
patients are willing to give up to live in perfect health or the amount of health patients are willing
to give up to survive for a longer period of time. These methods produce utility values for
individuals when they complete these exercises through face-to-face interviews (Drummond et
al., 2015), which can be burdensome and time-consuming. To overcome this limitation,
researchers often use pre-scored surveys which correspond to health state values that have been
derived from the general population. This method is called multi-attribute utility theory. Based
on this method, many multi-attribute health status classification systems have been devised, such
as the Health Utilities Index Mark 2 (HUI2), HUI3, the EQ-5D, and the SF-6D. The EQ-5D, in
particular, has been extensively used in studies to determine treatments' effect on a patient's
quality of life and has been used extensively in health economic evaluations (Dakin et al., 2018).

1.6.1 EQ-5D-5L
One of the most common preference-based measures is the EuroQol-5d (EQ-5D); a multiattribute health classification (generic) survey developed in the European Union (EU), designed
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to examine the QOL through five key areas or attributes; mobility; self-care; activities of daily
living (ADL); pain and anxiety. The original EQ-5D model consisted of three levels (EQ-5D3L), with each attribute providing three response levels; no problem; some problem; unable to
perform, extreme pain, or extreme anxiety. Research had indicated that the 3L system had ceiling
effects and that the survey could not detect changes in certain populations. As a result, a
modified version of the survey was published in 2009, consisting of five levels for each attribute:
the EQ-5D-5L survey. This survey proved to be more capable of detecting changes and has been
validated across multiple countries such as the UK, Canada, South Korea, Japan, China, and
Spain, to name a few (Janssen et al., 2018).
The widespread use of the survey is due to its good psychometric properties and ease of
administering it. The EQ-5D-5L consists of 5 questions, one for each attribute and five levels or
response options for each attribute, such as no problems, slight problems, moderate problems,
severe problems and unable to perform an activity or extreme pain and anxiety. When
participants complete the survey, a 5-digit code called the health index value is produced,
representing a specific health state. Since there are five attributes and five levels, the survey can
identify 3125 (55) health states, compared to the 245 (53) health states that could be identified in
the 3L version of the survey. Each health index value produced has a corresponding utility value
that is based on a value set derived using one of the direct elicitation methods mentioned before
for each country. The utility scores from all value sets will fall between 0 and 1; 0 represents a
health state equivalent to death for participants, while 1 represents a perfect health state. In
certain value sets, some of the derived utility values can be less than 0, and these represent health
states that are worse than death for participants. As Bilbao (2018) pointed out, the EQ-5D-5L
had a Cronbach's alpha of 0.86, a good correlation with WOMAC pain subscales with 0.688 and
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0.782 for pain and function subscales, and a large difference in know-groups validity between
the WOMAC and EQ-5D-5L and finally the EQ-5D-5L displayed high effect sizes (ES), and
standardized response means (SRM), with similar values being found by Jin and colleagues
along with good Guyatt Response Index (GRI) value, with similar results being found by Jin and
colleagues (2019).

1.7 Orthopedic studies and cost-utility studies
A systematic review by Nwachukwu and colleagues (2015) indicated that there had been an
increase in the number of CUA studies published over the past decade comparing total joint
arthroplasty to various forms of similar surgical treatments and study designs. Their study
identified 676 articles published between 1999 to 2014, of which 23 were determined to be of
high quality compared to a previous study that reviewed articles from 1975 to 2001, which only
identified 37 studies, of which only 11 qualified as CUA (Nwachukwu et al., 2015). Similar
examples include work by Lau and colleagues (2021), who conducted a systematic review of the
use of HRQOL and CUA within critical care. The study identified 80 CUA studies out of 8,926
possible studies and highlighted that difference exists in CUA methodology, questioning the
validity of comparing QALYS. They also noted that 70% of HRQOL/QALYS were extrapolated
from another source within studies that had multiple time points (Lau et al., 2021).
Similarly, Wisloff and colleagues (2014) conducted a systematic review of CUA published up to
2010. Their study aimed to identify the various methods of quantifying QALY gains across
published CUA and determine the transparency of reporting QALYS and their reported size in
gains (Wisloff et al., 2015). Of the 370 studies identified, the EQ-5D was the most common
instrument for measuring QALYs gained, while the TTO was the most common valuation
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method used, followed by VAS, SG and PTO (Person Trade-off), while 42 studies had used
mapping algorithms and 35 of those mapping studies had not specified their valuation method.
Finally, a systematic review by Primeau and colleagues (2021) assessed the quality of published
health economic evaluations within orthopedic populations and identified 93 health economic
evaluations (Primeau et al., 2021). Their study indicated that the health economic evaluations
conducted within Orthopedic sports medicine were of high quality, but nearly half of the studies
did not perform full economic evaluations. In addition, their study pointed out that the majority
of highly cited health economic evaluations were not of high quality in comparison to those
published within Orthopedic sports medicine, but they have encouraged more full economic
evaluations to be published to better understand effective ways of resource allocation (Primeau et
al., 2021). These examples indicate the increased prevalence of health economic studies within
medicine and health, its increased focus on CUA and its growing recognition across multiple
research areas.
Orthopedic studies have recently begun leveraging preference-based surveys to assess the
effectiveness of various therapies by comparing the QALYs gained from each treatment.
However, in instances where health preference data is not collected explicitly and there is a need
for health utility data, researchers have turned towards mapping strategies that allow the results
from disease-specific surveys that assess clinical outcomes to be converted into health utility
scores. Orthopedic studies have a particular use for these methods since many previous
orthopedic studies did not use generic surveys to obtain health utility data; however, they have
access to large databases that contain data from disease-specific surveys. For example, Dakin
and colleagues utilized mapping strategies to estimate EQ-5D utilities from Oxford Knee scores
from a patient population that underwent total knee replacements (Dakin et al., 2013). Similarly,
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multiple mapping algorithms have been published for converting disease-specific survey scores
into health utility scores, with research on the validity of these methods (Dakin et al., 2020).

1.8 Mapping Algorithms
Mapping refers to the use of an algorithm to convert scores from disease-specific surveys into
utility scores. Mapping is most useful for studies, clinical trials and assessment programs that
have not administered any generic utility surveys during the progression of the study and would
now like to add a health economic component to their study; most commonly a cost-utility study.
In instances where health utility data has not been collected, but disease-specific surveys have
been administered, mapping algorithms can convert those disease-specific scores into generic
utility scores to be used in cost-utility studies. Mapping is known as cross walking since it allows
researchers to predict health preferences from disease-specific or non-preference-based surveys.
A recent systematic review by Dakin and colleagues (2018) published a systematic review that
identified various mapping algorithms from patient-reported outcomes to the EQ-5D-3L or the
EQ-5D-5L surveys.
Additionally, Dakin and colleagues (2020) also published a database for the Health Economics
Research Center (HERC), which contains the various mapping algorithms published across
various disease categories and patient groups. The database and systematic review provide health
economic researchers with multiple sets of algorithms to use in CUA and highlights the crucial
role of mapping within medical research. From their database, three algorithms were identified
for converting WOMAC scores into utility scores. Such as those by Barton and colleagues
(2008), Xie and colleagues (2010) and Wailoo and colleagues (2014). The algorithms have been
most popular among clinicians and researchers and have been shown to have good external
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validity by Kaidaliri and Englund (2016). However, these algorithms were designed to convert
WOMAC scores into utility scores for the EQ-5D-3L survey and not the EQ-5D-5L survey.
Kaidalri and Englund noted that the linear regressions models used within the three algorithms
by Barton, Xie and Wailoo would underpredict and overpredict depending on the varying health
states and that these algorithms had a systematic bias, consequently cautioning against their use
(Kaidaliri & Englund, 2016).
Recently, Bilbao and colleagues (2020) have published new algorithms based on multiple
statistical methods such as general linear modelling, beta regression models, and Tobit models to
convert the WOMAC scores into the EQ-5D-5L scores. These models were proven to be able to
better predict utility values from WOMAC than those developed previously for the EQ-5D-3L
surveys; through higher adjusted R2 values (Bilbao et al., 2020). Previous studies by Xie (2010)
and Barton (2008) focused on predicting scores from the EQ-5D-3L models and indicated that
predicted utility scores could predict utility scores well but did not provide ICC values.
Additionally, Barton’s study revealed that the QALY gains from the predicted scores were
significantly different in some cases resulting in inaccurate conclusions for CUA. Finally, Bilbao
and Colleagues (2020) produced regression models which could be used in predicting the utility
scores from WOMAC scores for a Spanish population using the EQ-5D-5L index values for the
Spanish population. Their study produced multiple regressions (General Linear Model (GLM),
Tobit model and Beta regression models), which have not yet been externally validated. Their
results indicated that their preferred model was the GLM and the beta regression model, with
domains of the WOMAC being used as covariates within the models.
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1.9 Purpose: The study's primary objective is to determine the agreement between utility
scores derived from WOMAC and EQ-5D-5L questionnaires on patients who have undergone
TJR surgery on the hip or knee. A secondary objective is to compare agreement among
subgroups divided by the length of time post-operative: 1 year; 2 to 5 years; 5 to 10 years, and
over 10 years.
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Chapter 2
2 Methods
2.1 Study Design
Our study employed a retrospective cohort design among patients who had undergone total hip
and knee replacement surgery between June 2006 to December 2021. The study was approved
by the University of Western Ontario's Health Science Research Ethics Board for Research
involving human subjects and Lawson's approval.

2.2 Eligibility Criteria
We included individuals who had undergone total joint replacement surgery of the hip or knee at
University Hospital between June 2006 and December 2021. Patients had to be at least 1-year
post-operative and over the age of 18 years.
Participants were excluded if they were under 18; had undergone revision surgery, or did not
have a complete WOMAC and EQ-5D-5L survey at a minimum of 1-year post-operative.

2.2.1 Sample size
There were 500 eligible patients in the database. This sample size provided sufficient power to
provide estimates of agreement between the two scores (test-retest reliability = 0.90) with a
prespecified level of precision (0.10). (Bonnet, 2002) for the total sample and for the subgroups
of patients based on their post-operative time points: 1) 1 year; 2) 2 to 5 years; 3) 5-10 years;
4)>10 years. Additionally, to obtain good predictive accuracy the GLM mapping algorithm
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provided by Bilbao, a minimum of 400 patients were required, therefore, 500 participants would
also provide sufficient power to run the GLM (Bilabo, et al. 2020).

2.2.2 Data collection
An institutional clinical database was used to identify patients who underwent a primary total hip
or knee arthroplasty between 2006 to 2021. A retrospective review was performed to collect
eligible patient data through the same database. All patients who undergo TJR at University
Hospital are followed with patient-reported outcome measures, including the WOMAC and the
EQ-5D-5L, at multiple time points such as the 3-month and 1-year post-operative time points
and are further followed up every 1-2 years following surgery. The results from the
questionnaires are entered into the clinical institutional database, and a score is calculated with
standardized scoring algorithms. For the purposes of our study, we collected information
regarding the participants’ sex; age; date of most recent follow-up visit; type of primary joint
replacement surgery (hip or knee), and their most recent WOMAC and EQ-5D-5L from their
latest available follow-up visit.
The data set was further divided into subgroups based on how long it has been since their
surgery. Subgroup 1 consisted of patients who were at the 1-year post-operation time point.
Subgroup 2 consisted of patients who were 2 to 5 years post-operative. Subgroup 3 consisted of
patients between 5 to 10 years post-operative and Subgroup 4 consisted of patients over 10 years
post-operative.
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2.3 Outcome measures
We collected demographic data, including age, sex, type of surgery (hip or knee), height (cm),
weight (kg), BMI (kg/m2), side of primary surgery (left or right), and follow-up visit time point.
The outcome measures used in this study are the EQ-5D-5L and the WOMAC survey. The EQ5D-5L is a generic survey that assesses the overall quality of life in patients, while the WOMAC
is a disease-specific survey that is aimed at evaluating the pain, stiffness and function of the hip
or knee joints within OA patients. Both have been shown to have good measurement properties
among patients with OA and who have undergone TJR (Lundgren-Nilsson et al., 2018; Bilbao et
al., 2020)). The scores for each of the questions for the WOMAC surveys and the scores for each
of the domains (pain, stiffness and physical function) were collected. In our study, the WOMAC
scores for each of the domains were converted to a scale of 100, along with the WOMAC total
score being out of 100. The higher scores indicated better health, while lower values indicated
worse levels of health. The responses for the EQ-5D-5L surveys were combined into 5-digit
health profiles which were used to identify the health utility index values from the Canadian EQ5D-5L TTO value set (Xie et al., 2016). The participants were divided into subgroups based on
the number of years post-op. Finally, we also collected information on the primary diagnosis
factor for the surgery.

2.4 Mapping Algorithm
Based on the mapping algorithms developed by Bilbao and colleagues (2020), we created a
General Linear Model (GLM) mapping algorithm to covert the WOMAC scores into a utility
score.
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The General Linear Model (GLM) utilized the following variables as covariates within the model
to convert the WOMAC scores into utility scores: Pain2 + Pain3 + Function + Pain x Function.
Each of the covariates for both the models required the original WOMAC values to be raised by
powers and then be divided by 100 or 10,000 or required the values of the subscales to be
multiplied and divided by 100, such as for the Pain X function covariate in the GLM models.

2.5 Plan for Analysis
Demographics for the study sample were summarized using means and Standard Deviations
(SD) or frequencies and proportions where applicable. In addition, we calculated the distribution
of the EQ-5D-5L utility scores and the predicted utility scores from the WOMAC, along with
their mean and SD values. All data were analyzed using R version 4.0.4.

2.5.1 Agreement
To identify the level of agreement between the converted WOMAC utility and EQ5D utility
values, we calculated the Intraclass Correlation Coefficient (ICC) (two-way mixed model with
measures of consistency) and its 95% confidence interval. We considered ICC values below 0.5
to indicate poor reliability, 0.5 – 0.75 indicate moderate reliability,0.75 and 0.90 indicate good
reliability and values > 0.90 indicate excellent reliability (Koo and Li, 2016).
We also calculated the standard error of measurement (SEM) and its 95% CI. The ICC provides
information about the total variance (between and within-subject variability and random error),
whereas the S.E.M. expresses individual measurement error only, without the influence of
variance among patients.

22

2.5.2 Validity
To assess the validity of the converted WOMAC utility score, we performed a linear regression
to determine the ability of patients' converted utility scores on the WOMAC questionnaire to
predict the EQ-5D utility scores. To verify if our data met the assumptions of linear regression
(linearity; homoscedasticity; independence of observations, and normality of data), we
constructed residual vs fitted plots, quantile-quantile (qq) plots, scale-location plots, and
residuals vs leverage plots. The first assumption of linearity refers to the idea that the
relationship between the independent and dependent variables (Y and X) is linear. The second
assumption, homoscedasticity, is centred around the equal distribution of errors or residual
values, which is the difference between the actual and predicted utility scores in this case. The
third assumption is the independence of observations which relates to the idea that the Y and X
variables do not share any relations. Finally, the assumption of normality requires that residuals
are normally distributed.

2.5.3 Mean difference of utility scores
We conducted a paired t-test to identify if there were any significant differences between the
means of each utility score. Given our large sample size, we did not require the assumption of
normality to be met.

2.5.4 Bland Altman Plot
To visually display the agreement between the WOMAC and EQ-5D-5L scores, we created
Bland Altman plots which illustrate the magnitude of the difference between the two utility
measures and show the distribution of the difference values over the entire range of the utility
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score. The closer the data points fall on the central line, the better the agreement between the two
sets of measurements. We also displayed 95% confidence intervals around the mean difference.
The graph also has two limits of agreement set a 1.96 SD away from the mean, which means that
points that fall outside the confidence bands can have a significant amount of difference between
the two means and indicates not only the presence of outliers in our data but also the presence of
residual errors, these points can be considered to be extreme outliers. Residual errors are the
difference between the observed and predicted utility values.

2.6 Outliers
Finally, we assessed our data for outliers using percentiles and boxplots. The percentiles were
used to identify outliers that existed outside of 2.75% and 97.5% of the data. Boxplots for both
the predicted and observed utility scores were made to graphically see the outliers present in our
data. This was complemented by histograms displaying the distribution of the predicted and
observed scores for the data
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Chapter 3 Results
3.0 Results
A total of 500 participants were eligible for the study and were included in the analysis. The
mean age of the patients was 64.4 (SD = 8.9), with 311 participants being female and 189 male
(Table 1).
The mean EQ-5D-5L index value was 0.79 (0.18) (range -0.1 to 0.95). The mean total WOMAC
score was 79.05(19.9), and the mean converted WOMAC utility score was 0.79(0.14). The mean
values were similar for all subgroups (Table 2).
Characteristics
(mean, SD)

Total sample
population
N = 500

Age(years)
Sex (Female),
n(%)
Height, cm
Weight, kg

Subgroup 2
(2- 5 years)
N = 287

Subgroup 3 (5
– 10 years)
N = 116

Subgroup 4 (> 10
years)
N = 52

64.39 (SD = 8.88) 64.79 (10.67)
311(62.22%)
29 (64%)

65.13 (8.4)
173 (60.3%)

64.83 (9.09)
74 (63.7%

59.04 (7.64)
35 (67.3%)

167.48 (10.21)

167.85 (9.95)

166.8 (10.62)

167.46 (10.22)

94.19 (22.38)

166.82
(10.99)
93.83 (24.18)

94.30 (22.17)

92.05(22.99)

98.63 (20.4)

BMI, kg/, m2

33.54 (7.28)

33.46 (6.82)

33.45 (7.33)

32.94(7.02)

35.39 (7.86)

Primary THA (n)
Primary TKA

183
317

16
29

104
183

44
72

19
33

Operative Side
(n %)
Left

239

26

124

64

25

261

19

163

52

27

Right

Subgroup 1(
1 year)
N = 45

Table 3.1 Demographics Table - Sample population demographics and characteristics by the total sample
size and by subgroups
SD = standard deviation
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QoL Scores
(mean, SD)

Total sample
population
N = 500

Subgroup 1(< 1
year)
N = 45

Subgroup 2 (25 years)
N = 287

Subgroup 3 (5
– 10 years)
N = 117

Subgroup 4 (>
10 years)
N = 52

81.23 (20.84)

82.22 (16.74)

82.75 (21.68)

80.43 (18.57)

73.75 (22.81)

Function
score

79.56(21.02)

81.34 (18.82)

81.5 (21.73)

78.4 (18.44)

69.91 (21.93)

Stiffness score

73.95 (21.86)

73.33(22.23)

75.65 (22.45)

72.41 (20.56)

68.51 (20.49)

Total score

79 (19.91)

80.03(17.1)

80.8 (20.74)

77.77 (17.58)

71.23 (20.73)

WOMAC
Pain score

EQ-5D-5L
0.79 (0.18)
0.78 (0.2)
0.80 (0.19)
0.77 (0.17)
0.76(0.17)
utility index
Converted
0.79(0.14)
0.81(0.12)
0.80(0.15)
0.79(0.12)
0.73(0.15)
WOMAC utility
values
Table 3.2 Summary table for predicted and observed utility score. Summarizes the domain scores for the
total sample and subgroups along with the observed us and predicted utility values from the mapping
algorithm.
SD = standard deviation.

3.1 Mapping Algorithm
Using the mapping algorithm, we derived the following equation to covert the WOMAC to a
utility score:
Y = 0.129401 + 0.010297 (Pain2/100) – 0.005955(Pain3/10000) + 0.007689(Function scores) 0.004352(Pain x Function/100).
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The residual standard error was identified as 0.1192, indicating that when the model predicts
utility scores, it does so with an error of 0.1192. The model had a Multiple R2 value of 0.58 and
an adjusted R2 value of 0.58, indicating a good fit for the model.

3.2 Agreement
3.2.1 Agreement between utility values
The mean scores for the predicted utility index value were 0.79 (0.14), with a minimum value of
0.15, a maximum value of 0.91 and a range of 0.75. We found good agreement between the EQ5D-5L utility scores and the converted WOMAC scores (ICC = 0.85, 95% confidence interval
=0.82 to 0.87). The Standard error of measurement (SEM) for the predicted utility scores for the
total sample was calculated to be 0.054 (0.14 *√1 − 0.85),. indicating that the amount of error
surrounding the predicted value is 0.054, which is low, providing further evidence of good
agreement between the predicted and observed utility values.
Similarly, the ICC values based on the GLM for subgroups 1 – 4 have been summarized in
table3.3
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Subgroups

ICC values

95 % Confidence interval

(C,2)

(CI)

Subgroup 1 (N = 45)

0.777

0.592<ICC< 0.877

Subgroup 2 (N = 287)

0.879

0.848<ICC<0.904

Subgroup 3 (N = 116)

0.798

0.709<ICC<0.86

Subgroup 4 (N = 52)

0.811

0.67<ICC<0.891

Table 3.3 Intraclass Correlation (ICC) for subgroups. C stands for consistency, and 2 represents two
surveys. CI = Confidence interval

The mean ICC values for each of the subgroups indicate that there is good agreement between
the two methods. The subgroups with a lower number of participants had wider confidence
intervals, while those with a larger sample size had a narrower 95% CI, as seen for subgroups 2
and 3. Despite the wide confidence intervals, the 95% CI for the ICC values for all subgroups
remained within the moderate to good and good to excellent reliability.

3.3 Validity
To identify whether the assumptions for linear regression were met, normality plots for the data
and linear regression analysis to compare the predicted and observed utility scores were
conducted.
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3.3.1 Normality plots for data

Figure 3.1. Normality plots for the linear model. Comparing observed utility scores to the predicted
utility scores from the data. The top left graph displays the residuals vs fitted graph, where the fitted
values (x-axis) are compared to the residual’s values (y-axis) or differences between the predicted and
observed utility values. The graph on the top right is a normal Q-Q plot comparing the theoretical
quantiles to standardized residuals. The graph on the bottom left is a scale-location graph, comparing the
fitted values to the square-rooted standardized residuals. The graph on the bottom right is a residual vs
leverage graph, comparing the leverage of individual points to the standardized residuals; the Cooks
Distance of note is 0.5.

The residuals vs fitted graph indicate that there is a large density of values towards the edge of
the graph, meaning that the residuals are fairly lower at the higher utility scores than those at the
lower scores where the points are more sparse. The red lines for the graph are relatively flat, with
the tail end at the lower end of the fitted values being below the zero line. Ideally, the redline and
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the dotted line would remain parallel or on top of each other, indicating that no residuals are
present in the data. However, since this is not the case, it indicates that the data is not linear.
Similarly, since there is a cluster of points at the end of the graph, the assumptions of
homoscedasticity have been violated, indicating that there is an unequal distribution of error
variances in the data.
The Quantile-Quantile (QQplot) compares the quantiles and the standardized residuals. The
graphs for the model show that the data is not following the 45-degree line perfectly, as it would
have had the distribution of the data been normal. But since the data points on the lower halves
of the QQ plot strays from the 45-degree line while the upper half remains on the dotted line, this
indicates negative skewness in the distribution of points, along with the presence of a heavy tail.
For the scale-location plots for the linear model, the lack of homoscedastic data indicates
heteroskedasticity or the unequal distribution of variances with the data. This is seen with the red
line slowly declining towards the edge of the graph. Had the data been homoscedastic, the red
line would have remained fairly flat, indicating that the variance distribution is equal.
Finally, the residuals vs leverage graphs for both models suggest the presence of influential
points that can skew the data. The red lines on both graphs show that the lines travel upward and
then downward, indicating the presence of both positive and negative residuals, respectively.
Additionally, since the outliers on both graphs are identified with numbers, and since the dotted
red lines are present on both graphs, it indicates that these outliers have significant leverage
indicating that their residuals are large enough to change the slope of the redline.
Figure 3.3 displays a histogram of the distribution of the utility index scores from the EQ-5D-5L
surveys, and the skewness towards the right indicates that the data is not distributed normally,
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with a large proportion of utility index scores being found on the right, indicating that on average
the patients believe that they are in the best possible health state that they can be in. The lowest
utility index value was -0.1023, and the highest value was 0.9490, with skewness of -2.05 and a
kurtosis factor of 4.87. This also provides more evidence on the abnormal distribution of our
data. Figure 3.4 shows the distribution of the WOMAC total scores within the sample, with the
largest concentration of scores at 100, indicating good health and joint function. The mean value
for total score from the WOMAC surveys of patients was 79.08 (19.9). These plots help illustrate
the unequal distribution of values for the EQ-5D-5L and for the WOMAC, with our data set.

Figure 3.2. Represents the distribution of EQ-5D-5L utility index values within the sample population and
its frequency.
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Figure 3.3. Distribution of total WOMAC scores across the sample population.

3.3.2 Linear Regression analysis

Coefficients

Estimate

5%

95%

Standard Error
of measurement

Intercept
Predicted EQ5D-5L utility
scores from
WOMAC`

-0.0000632
1.00068

-0.05007984
0.93756961

0.05013337
1.06232743

0.0305
0.054

Residual

0.119

Multiple R2
Adjusted R2

0.5825
0.5816

Table 3.4Linear regression. 95% CI for coefficients for the model. The associated p value for the model
was < 0.001.
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Figure.3.4 Linear regression between predicted and observed utility scores, with a 95% confidence band
around the regression line, for the overall sample.

The converted utility value from the WOMAC questionnaires were a significant predictor of
utility values provided by the EQ-5D-5L (p<0.001). The standard error of measurement was
0.054 and a residual error of 0.119 for the model. This means that the predicted values had an
error of 0.054 from the true score and that the model predicts utility values with an error of 0.119
on average.

3.4 Mean Difference in utility scores
The mean difference between the two utility scores on the paired t-test was 0.000087 with a 95%
CI (-0.0103 – 0.0105) p= 0.987. Since the p-value is higher than 0.05, we cannot reject the null
hypothesis that the true difference between the two variables is equal to 0. This is also evident
when looking at the mean difference value of 0.000087, which means that there is little or no
difference in the means. With similar being presented across the subgroups as seen in table 3.5.
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Mean difference

Lower CI

Upper CI

P values

Total Sample

0.000087

-0.010

0.010

0.987

Subgroup 1

0.028

-0.013

0.069

0.182

Subgroup 2

-0.0054

-0.018

0.0073

0.403

Subgroup 3

0.016

-0.0058

0.039

0.1438

Subgroup 4

-0.030

-0.067

0.0060

0.1003

Table 3.5 Mean difference and 95% CI around mean difference for the total sample and for subgroups.

3.5 Bland Altman Plots
Figure 3.5 shows a Bland Altman plot which compares the means of the two scores and the
differences between the two scores.
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Figure. 3.5 Bland Altman plot comparing the two methods for the entire sample. Since there is a large
cluster of points close to the zero line, we can interpret it as both methods having good agreement in
producing utility values.

As shown in Figure 3.5, the largest density of points exists between the bias lines and the two
limits, and a few points that exist outside the limits indicating that the two utility scores have
good agreement.
Additionally, when looking at the associated Bland Altman plots for each of the subgroups, the
subgroups with higher ICC values such as subgroups 2 and 3, have more data points that fall
within the 95% confidence limits than subgroups 1 and 4. Their points are closer to the middle
line of no difference, indicating that the amount of residual error present within those points is
lower than those outside the limits.

Figure 3.6. Bland Altman plot for subgroup 1.
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Figure3.7. Bland Altman plot for subgroup 2.

Figure 3.8. Bland Altman plot for subgroup 3.
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Figure 3.9. Bland Altman plot for subgroup 4.

3.6 Outliers
A total of 33 outliers were identified within the dataset with 10 outliers being commonly
reported for both the predicted utility values and the EQ-5D-5L utility scores. These outliers
were identified using the quantile function in R. The lower boundary was defined as 2.5%, and
the upper boundary was defined as 97.5%. Therefore, any points that fell outside the boundary
for both the surveys were identified as outliers. A table has been provided in Appendix D which
summarizes the findings for the outliers for both surveys, while the boxplot provided in Figure 3.
10 provides a visual display of the number of outliers present within each of the surveys.
Individuals identified as outliers were mostly from subgroup 2 with 26 patients. All of the
outliers either had low health profiles or high health profiles. Similarly, these individuals also
had low predicted utility values based on the GLM model. This could be due to the model either
underpredicting or overpredicting scores for individuals with low or high health states.
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Figure 3.10. Boxplots for the predicted utility values from the WOMAC survey and the observed utility
values for the EQ-5D-5L for our data.

When the outliers were removed, the ICC value for the total sample fell to 0.78 and 95% CI of
0.74 to 0.82. The decrease in agreement is due to the lower number of participants present in the
data, which now stands at 464 participants. The Bland Altman plot for the new dataset, displayed
below in figure 3.11 shows fewer points present below the lower agreement band. Similarly, the
data points that were common outliers for both the EQ-5D-5L and the predicted utility scores
from the WOMAC had an ICC value of 0.415 and 95% CI between -1.591 to 0.868. These
results indicate that there is poor agreement between the data points that were commonly
identified as outliers for both surveys. Additionally, the Bland Altman plot for the common
outliers has been provided in figure. 3.12.
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Figure 3.11. Bland Altman plot with outliers removed.

Figure 3.12. Bland Altman plot for outliers that were common for both surveys.
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Chapter 4.0
4.0 Discussion
The purpose of this study was to measure the agreement between converted utility scores and
EQ-5D-5L utility scores. We found good agreement between the two measurement instruments
for the sample and found moderate to good agreement for subgroups. The paired t-test indicates
that there is an extremely small difference between the two mean scores that was not statistically
significant. When combined with the ICC value for the sample population, of 0.85, with a 95%
CI (0.82 – 0.87), it is evident that there is good agreement between the WOMAC predicted
utility values and the observed utility scores from the EQ-5D-5L. However, the ICC values for
the subgroups were 1 year post-op and those over 10 years post-op had wider confidence
intervals compared to the other groups, indicating greater uncertainty. These groups had fewer
patients, which may have contributed to the greater uncertainty, despite the small mean
difference values reported in Table 3.5.
We found that individuals who had lower utility index values and low total scores on the
WOMAC had lower agreement. The mean ICC value for outliers was 0.41 with a 95% CI
between -1.6 to 0.87, which indicates poor agreement between the WOMAC predicted utility
scores and the EQ-5D-5L observed scores. The utility scores generated by the EQ-5D-5L
represent the HRQOL weight multiplied by time to derive QALYs for each course of action
within health economic evaluations, CUA in particular. While our results indicate that there is
good agreement between the predicted and observed utility scores, the actual QALYs being
generated will differ, as demonstrated by Barton (2008). Our results indicate that the HRQOL
values being generated from the WOMAC will be much closer to the actual values than those
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previously generated from older mapping models, however, they will not be an exact match to
the actual utility values. Therefore, in clinical practice, mapping algorithms can be an effective
tool in identifying an approximation of the utility of TJR in patients who have undergone the
procedure. But as Barton, Xie, and Bilbao have noted, mapping algorithms, including the
algorithm used in this study can overpredict certain health states, as seen in the outliers for low
health states (Barton, et al., 2008 ; Xie et al., 2010 ; Bilbao et al. 2020). Therefore, when
interpreting the results from mapped surveys, caution must be applied for using this method to
identify utility.
Our results are consistent with the ICC values provided by Bilbao and colleagues (2020) (ICC=
0.826). Their study consisted of patients diagnosed with hip and knee OA and compared
agreement between the observed utility values and predicted utility values from the EQ-5D-5L
and WOMAC scores from their baseline to the values generated at a second timepoint, 6 months
later. The baseline results were used to identify mapping algorithms, while their 6-month time
point results were used to internally validate their model, along with the relevant statistics for
prediction and agreement. Their study produced 3 types of mapping algorithms, of which their
preferred models were the GLM and beta regression models. The GLM and Beta regression
models had good ICC values with 0.826 (0.800 – 0.851) and 0.830 (0.804 – 0.855), indicating
good agreement. Their adjusted R2 value for the GLM was found to be 0.61. Our study added to
their results, by using their mapping algorithm on a Canadian population and thereby externally
validating their GLM. Additionally, we used a Canadian EQ-5D-5L TTO value set (Xie et al.,
2016).
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Similarly, Xie and colleagues (2010) mapped the WOMAC onto the EQ-5D-3L within a
Singaporean population diagnosed with knee OA , using a Japanese EQ-5D-3L scoring
algorithm. Their study developed mapping algorithms based on the Ordinary Least
Squares(OLS) and Censored Least Absolute Deviation (CLAD)s methods. Their preferred model
was the OLS with WOMAC domain scores being used as variables since it had the best adjusted
R2 value of 0.499. The primary focus of their study was the predicted accuracy between the
predicted values and the observed EQ-5D-3L utility values. Their study also provided
information on individual and group differences of the predicted and observed scores. While
knowing the absolute differences in values can be helpful, it does not provide an exact scale or
magnitude of the agreement, like the ICC used in our study.
Barton and colleagues (2008), also developed mapping algorithms for converting the WOMAC
to the EQ-5D-3L utility scores, within the UK population using the UK value set. Their study
was comprised of individuals diagnosed with knee pain who were a part of the Lifestyle
Interventions for Knee Pain (LIKP) study that compared four sets of interventions aimed at
reducing knee pain. The primary outcome measures were the WOMAC and the EQ-5D-3L
surveys, with participants being asked to complete the surveys at multiple time points such as
baseline, 6 months, 12 months, and 24 months. Their adjusted R 2 value was 0.313 for their
preferred model. Their study used the utility scores within a CUA to identify the QALY gains
and the observed and predicted incremental cost per QALY. They identified that there were the
differences in the incremental cost per QALY estimates based on the utility value generated from
the WOMAC to the actual utility values from the EQ-5D-3L.
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4.1 Strengths and Limitations
Our study is the first to incorporate a mapping algorithm for the WOMAC to obtain utility scores
for the EQ-5D-5L using the Canadian EQ-5D-5L TTO value set (Xie et.al., 2016). Additionally,
our study was large enough to run a GLM and thus provides further evidence for Bilbao’s GLM
by contributing to the external validity of the mapping algorithm.

In terms of limitations for the study, our study did not implement all 3 mapping algorithms
constructed by Bilbao (2020), therefore, we could not compare the agreement statistic across all
models based on a Canadian population. Implementing more complex models such as the Beta
regression model may account for more errors or better prediction of utility values.

Further, as our sample consisted entirely of post-operative total joint replacement surgery
patients, the majority had high utility values, and our sample did not have a representative
distribution of possible utility scores. Therefore, future studies are needed to evaluate agreement
among other orthopaedic patient populations, such as those preoperative, who may have lower
health states.
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Chapter 5
5.0 Conclusion
Our findings indicate that the practice of using mapping algorithms to ascertain utility scores
from disease-specific surveys such as the WOMAC can produce accurate results with a SEM for
predicted values of 0.054. While the utility index values generated from mapping algorithms do
not provide perfect agreement with utility scores from preference-based surveys, they provide
values that are closer to the observed utility scores than previous mapping algorithms published
by Xie (2010) and Barton (2008), as seen in the predictive ability of the Bilbao model in the
adjusted R2 values.

5.1 Future Directions
Future studies can identify the impact of different utility values generated from mapping
algorithms on the incremental cost utility ratios to understand the underlying implications of
using mapping algorithms to determine the value of health interventions.
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Appendix B

EQ-5D-5L
Under each heading please tick the ONE box that best describes your health TODAY.
Mobility
I have no problems in walking about

☐

I have slight problems in walking about

☐

I have moderate problems in walking about

☐

I have severe problems in walking about

☐

I am unable to walk about

☐

Self care
I have no problems washing or dressing myself

☐

I have slight problems washing or dressing myself

☐

I have moderate problems washing or dressing myself

☐

I have severe problems washing or dressing myself

☐

I am unable to wash or dress myself

☐

Usual activities (eg. work, study, housework, family or leisure activities)
I have no problems doing my usual activities

☐

I have slight problems doing my usual activities

☐

I have moderate problems doing my usual activates

☐

I have severe problems doing my usual activities

☐

I am unable to do my usual activities

☐

Pain/ discomfort
I have no pain or discomfort

☐

I have slight pain or discomfort

☐

I have moderate pain or discomfort

☐
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I have severe pain or discomfort

☐

I have extreme pain or discomfort

☐

Anxiety/Depression
I am not anxious or depressed

☐

I am slightly anxious or depressed

☐

I am moderately anxious or depressed

☐

I am severely anxious or depressed

☐

I am extremely anxious or depressed

☐
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Appendix C

WOMAC
A. Think about the pain you felt in the hip/knee during the last 4 months
Question: How
much pain do you
have?
1. Walking on a
flat surface
2. Going up or
down stairs
3. At night while in
bed, pain disturbs
your sleep
4. Sitting or lying
5. Standing upright

None

Mild

Moderate

Severe

Extreme

0

1

2

3

4

0

1

2

3

4

0

1

2

3

4

0
0

1
1

2
2

3
3

4
4

B. Think about the stiffness (not pain) you felt in your hip/knee during the last 4 weeks.
Stiffness is a sensation of decreased ease in moving your joint.
6. How
severe is your
stiffness after
first
awakening in
the morning?
7. How
severe is your
stiffness after
sitting, lying
or resting
later in the
day?

None
0

Mild
1

Moderate
2

Severe
3

Extreme
4

0

1

2

3

4

C. Think about the difficulty you had in doing the following physical activities due to
your hip/knee during the last 4 weeks. By this we mean your ability to move around
and look for yourself.
Question:
what degree
of difficulty

None

Mild

Moderate

Severe

Extreme

56

do you
have?
8.
Descending
stairs
9. Ascending
stairs
10 Rising
from sitting
11. Standing
12. Bending
to the floor
13. Walking
on a flat
surface
14. Getting in
and out of a
car, or on or
off a bus
15. Going
shopping
16. Putting
on your socks
or stockings
17. Rising
from bed
18. Taking
off your
socks or
stockings
19. Lying in
bed
20. Getting in
or out of a
bath
21. Sitting
22. Getting
on or off the
toilet
23.
Performing
heavy
domestic
duties

0

1

2

3

4

0

1

2

3

4

0

1

2

3

4

0
0

1
1

2
2

3
3

4
4

0

1

2

3

4

0

1

2

3

4

0

1

2

3

4

0

1

2

3

4

0

1

2

3

4

0

1

2

3

4

0

1

2

3

4

0

1

2

3

4

0
0

1
1

2
2

3
3

4
4

0

1

2

3

4
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24.
Performing
light
domestic
duties

0

1

2

3

4
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Appendix D

Outliers tables
Table 6 Outliers identified based on the utility from the EQ-5D-5L utility index values
Study ID

Age

Demographic

EQ-5D-5L

Eq-5d-5l

WOMAC

Predicted

health

utility index

total scores

utility score

profile

Hip007

59.5589

Male

43443

Hip084

58.05479

Female

41444

Hip131

63.62466

Male

Knee040

61.7863

Knee041

from Womac

0.205684816

36.04

0.458320919

0.174430248

42.04850006

0.487615785

54554

-0.064662124

4.801469803

0.174630389

Male

43443

0.205684816

36.04

0.458320919

65.81096

Male

43443

0.205684816

36.04

0.458320919

Knee047

44.81096

Female

54555

-0.102300456

3.188240051

0.153875545

Knee048

45.54247

Female

54555

-0.102300456

3.188240051

0.153875545

Knee070

69.14795

Female

44443

0.143931465

24.90439987

0.300941073

Knee179

64.2274

Male

54541

0.16088293

22.7852993

0.352262059

Knee180

65.11233

Male

54541

0.16088293

22.7852993

0.352262059

Knee198

68.51233

Male

55543

0.039785301

28.11179924

0.366017335

Knee250

59.73699

Female

43444

0.082788317

35.0705986

0.412517011
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Table 7 . Outlier identified based on the predicted utility values derived from the WOMAC
survey.
Study ID

Age

Demographic

EQ-5D-

Eq-5d-5l

WOMAC

Predicted

5L health

utility index

total scores

utility score

profile

from Womac
0.866965901

Hip018
Hip059

59.65479 Male
63.90959 Male

11122
11122

Hip060

68.22466 Male

11122

0.866965901

92.65000153

0.903598438

Hip089

63.64932 Female

11221

0.885146969

97.90000153

0.903598438

Hip131

63.62466 Male

54554

-0.064662124

4.801469803 0.174630389

Knee022

70.4411

Female

21121

0.865736296

81.625

Knee047

44.81096 Female

54555

-0.102300456

3.188240051 0.153875545

Knee048

45.54247 Female

54555

-0.102300456

3.188240051 0.153875545

Knee070

69.14795 Female

44443

0.143931465

24.90439987

0.300941073

Knee073

67.38356 Female

33441

0.345388032

28.86619949

0.429938079

Knee081

78.99452 Female

42221

0.671676063

97.90000153

0.903598438

Knee166

67.41644 Male

41433

0.457124353

21.13380051

0.293478548

Knee179

64.2274

Male

54541

0.16088293

22.7852993

0.352262059

Knee180

65.11233 Male

54541

0.16088293

22.7852993

0.352262059

Knee198

68.51233 Male

55543

0.039785301

28.11179924

0.366017335

Knee220

72.69863 Male

11111

0.948967801

97.90000153

0.903598438

Knee227

69.19726 Male

31331

0.743590266

23.3484993

0.296180264

0.866965901

90.55000305 0.9065585
95.27500153 0.903598438

0.899880688
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Knee239

61.51507 Male

11111

0.948967801

93.69999695

0.906627813

Knee250

59.73699 Female

43444

0.082788317

35.0705986

0.412517011

Knee288

59.58082 Female

32241

0.531941441

32.4455986

0.412517011

Knee289

60.11781 Female

32241

0.531941441

32.4455986

0.412517011
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